Jurkat-Human PD-1/LAG-3 (Luc)-Reporter Cell

Introduction

The Jurkat-Human PD-1/LAG-3 (Luc)-Reporter Cell is engineered to express the NFAT response element driving luciferase expression systems and the receptors full-length human PD-1 (Uniprot: Q15116) and LAG-3 (Uniprot: P18627-1), which can be used to evaluate the synergistic effect of anti-human PD-1 and anti-human LAG-3 antibody. When co-cultured with target cells expressing human PD-L1 and MHCⅡ, the PD-1/PD-L1 and LAG-3/MHCⅡ interactions inhibit TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 and LAG-3/MHCⅡ interactions by the simultaneous addition of anti-PD-1 or anti-PD-L1 and anti-LAG-3 antibodies releases the inhibitory signals and results in TCR activation and NFAT-mediated luminescence.

Application

Screen for anti-human PD-1 or/and anti-human LAG-3 antibody

Background

PD-1 (Programmed Cell Death Protein 1) is an inhibitory receptor expressed on activated T cells, B cells, and NK cells. It binds to PD-L1/PD-L2 on tumor cells and APCs, delivering inhibitory signals that suppress T cell function and promote immune tolerance. PD-1 blockade is a cornerstone of cancer immunotherapy.

Product Information